262 related articles for article (PubMed ID: 35892315)
21. The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
Cliff J; Jorgensen AL; Lord R; Azam F; Cossar L; Carr DF; Pirmohamed M
Crit Rev Oncol Hematol; 2017 Dec; 120():127-140. PubMed ID: 29198326
[TBL] [Abstract][Full Text] [Related]
22. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.
Schneider BP; Li L; Radovich M; Shen F; Miller KD; Flockhart DA; Jiang G; Vance G; Gardner L; Vatta M; Bai S; Lai D; Koller D; Zhao F; O'Neill A; Smith ML; Railey E; White C; Partridge A; Sparano J; Davidson NE; Foroud T; Sledge GW
Clin Cancer Res; 2015 Nov; 21(22):5082-5091. PubMed ID: 26138065
[TBL] [Abstract][Full Text] [Related]
23. Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study.
Zhai J; Sun X; Zhao F; Pan B; Li H; Lv Z; Cao M; Zhao J; Mo H; Ma F; Xu B
Breast; 2023 Feb; 67():36-45. PubMed ID: 36586272
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.
Sucheston-Campbell LE; Clay-Gilmour AI; Barlow WE; Budd GT; Stram DO; Haiman CA; Sheng X; Yan L; Zirpoli G; Yao S; Jiang C; Owzar K; Hershman D; Albain KS; Hayes DF; Moore HC; Hobday TJ; Stewart JA; Rizvi A; Isaacs C; Salim M; Gralow JR; Hortobagyi GN; Livingston RB; Kroetz DL; Ambrosone CB
Pharmacogenet Genomics; 2018 Feb; 28(2):49-55. PubMed ID: 29278617
[TBL] [Abstract][Full Text] [Related]
25. Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.
Hjorth CF; Damkier P; Stage TB; Feddersen S; Hamilton-Dutoit S; Rørth M; Ejlertsen B; Lash TL; Ahern TP; Sørensen HT; Cronin-Fenton D
Breast Cancer Res Treat; 2022 Jul; 194(2):353-363. PubMed ID: 35501422
[TBL] [Abstract][Full Text] [Related]
26. Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Tanabe Y; Shiraishi S; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y; Shimizu C
BMC Cancer; 2020 Apr; 20(1):325. PubMed ID: 32295642
[TBL] [Abstract][Full Text] [Related]
27. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
Chan YN; Jheng YW; Wang PJ; Chen CY; Lin MW; Wang YJ
Clin J Oncol Nurs; 2019 Oct; 23(5):494-501. PubMed ID: 31538967
[TBL] [Abstract][Full Text] [Related]
28. Taxane-induced neuropathy: How serious is this problem for patients with early breast cancer?
Nicolae R; Uccellini A; Siderov J; Mellerick A; Wong V; Yeo B
Asia Pac J Clin Oncol; 2023 Apr; 19(2):e118-e127. PubMed ID: 35692105
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of the traditional Chinese medicine, Buyang Huanwu Decoction, at preventing taxane-induced peripheral neuropathy in breast cancer patients: A prospective, randomized, controlled study.
Luo F; Wan D; Liu J; Chen D; Yuan M; Zhang C; Liu Q
Medicine (Baltimore); 2024 Mar; 103(9):e37338. PubMed ID: 38428887
[TBL] [Abstract][Full Text] [Related]
30. CYP2C8 rs11572080 and CYP3A4 rs2740574 risk genotypes in paclitaxel-treated premenopausal breast cancer patients.
Attia HRM; Kamel MM; Ayoub DF; Abd El-Aziz SH; Abdel Wahed MM; El-Fattah SNA; Ablel-Monem MA; Rabah TM; Helal A; Ibrahim MH
Sci Rep; 2024 Apr; 14(1):7922. PubMed ID: 38575662
[TBL] [Abstract][Full Text] [Related]
31. Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.
De Iuliis F; Salerno G; Taglieri L; Scarpa S
Cancer Chemother Pharmacol; 2015 Oct; 76(4):679-90. PubMed ID: 26198313
[TBL] [Abstract][Full Text] [Related]
32. Taxane-induced peripheral neuropathy and quality of life in breast cancer patients.
Salehifar E; Janbabaei G; Alipour A; Tabrizi N; Avan R
J Oncol Pharm Pract; 2020 Sep; 26(6):1421-1428. PubMed ID: 31937190
[TBL] [Abstract][Full Text] [Related]
33. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Bergmann TK; Gréen H; Brasch-Andersen C; Mirza MR; Herrstedt J; Hølund B; du Bois A; Damkier P; Vach W; Brosen K; Peterson C
Eur J Clin Pharmacol; 2011 Jul; 67(7):693-700. PubMed ID: 21327421
[TBL] [Abstract][Full Text] [Related]
34. Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
Lee MY; Apellániz-Ruiz M; Johansson I; Vikingsson S; Bergmann TK; Brøsen K; Green H; Rodríguez-Antona C; Ingelman-Sundberg M
Pharmacogenomics; 2015; 16(9):929-37. PubMed ID: 26115084
[TBL] [Abstract][Full Text] [Related]
35. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.
de Graan AJ; Elens L; Sprowl JA; Sparreboom A; Friberg LE; van der Holt B; de Raaf PJ; de Bruijn P; Engels FK; Eskens FA; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
Clin Cancer Res; 2013 Jun; 19(12):3316-24. PubMed ID: 23640974
[TBL] [Abstract][Full Text] [Related]
36. The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.
Su Y; Huang J; Wang S; Unger JM; Arias-Fuenzalida J; Shi Y; Li J; Gao Y; Shi W; Wang X; Peng R; Xu F; An X; Xue C; Xia W; Hong R; Zhong Y; Lin Y; Huang H; Zhang A; Zhang L; Cai L; Zhang J; Yuan Z
J Natl Cancer Inst; 2020 Jan; 112(1):55-62. PubMed ID: 31093677
[TBL] [Abstract][Full Text] [Related]
37. Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance).
Boora GK; Kanwar R; Kulkarni AA; Abyzov A; Sloan J; Ruddy KJ; Banck MS; Loprinzi CL; Beutler AS
Cancer Med; 2016 Apr; 5(4):631-9. PubMed ID: 26763541
[TBL] [Abstract][Full Text] [Related]
38. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for taxane-induced peripheral neuropathy in patients with breast cancer.
Liang C; Zhang Y; Chen QY; Chen WF; Chen MZ
Asia Pac J Clin Oncol; 2024 Apr; 20(2):220-227. PubMed ID: 36658674
[TBL] [Abstract][Full Text] [Related]
40. Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.
Demurtas S; La Verde N; Rota S; Casazza G; Montrasio C; Cheli S; Cona MS; Dalu D; Fasola C; Ferrario S; Filipazzi V; Gambaro A; Tosca N; Clementi E
Pharmacogenomics J; 2021 Aug; 21(4):491-497. PubMed ID: 33649523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
